Small Extracellular Vesicles in the Pericardium Modulate Macrophage Immunophenotype in Coronary Artery Disease

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC: Basic to Translational Science Pub Date : 2024-09-01 DOI:10.1016/j.jacbts.2024.05.003

Soumaya Ben-Aicha PhD , Maryam Anwar PhD , Gemma Vilahur PhD , Fabiana Martino PhD , Panagiotis G. Kyriazis MSc , Natasha de Winter MSc , Prakash P. Punjabi MD, PhD , Gianni D. Angelini MD , Susanne Sattler PhD , Costanza Emanueli PhD

{"title":"Small Extracellular Vesicles in the Pericardium Modulate Macrophage Immunophenotype in Coronary Artery Disease","authors":"Soumaya Ben-Aicha PhD , Maryam Anwar PhD , Gemma Vilahur PhD , Fabiana Martino PhD , Panagiotis G. Kyriazis MSc , Natasha de Winter MSc , Prakash P. Punjabi MD, PhD , Gianni D. Angelini MD , Susanne Sattler PhD , Costanza Emanueli PhD","doi":"10.1016/j.jacbts.2024.05.003","DOIUrl":null,"url":null,"abstract":"<div><div>Coronary artery disease (CAD) is a major health issue. This study focused on pericardial macrophages and small extracellular vesicles (sEVs) in CAD. The macrophages in CAD patients showed reduced expression of protective markers and unchanged levels of proinflammatory receptors. Similar changes were observed in buffy-coat–derived macrophages when stimulated with CAD pericardial fluid-derived sEVs. The sEV contained miRNA-6516-5p, which inhibited CD36 and affected macrophage lipid uptake. These findings indicate that sEV-mediated miRNA actions contribute to the decrease in protective pericardial macrophages in CAD.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 9","pages":"Pages 1057-1072"},"PeriodicalIF":8.4000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452302X24001888/pdfft?md5=a5069912a4a92134ebda4433d621f0d5&pid=1-s2.0-S2452302X24001888-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X24001888","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Coronary artery disease (CAD) is a major health issue. This study focused on pericardial macrophages and small extracellular vesicles (sEVs) in CAD. The macrophages in CAD patients showed reduced expression of protective markers and unchanged levels of proinflammatory receptors. Similar changes were observed in buffy-coat–derived macrophages when stimulated with CAD pericardial fluid-derived sEVs. The sEV contained miRNA-6516-5p, which inhibited CD36 and affected macrophage lipid uptake. These findings indicate that sEV-mediated miRNA actions contribute to the decrease in protective pericardial macrophages in CAD.

查看原文本刊更多论文

心包中的细胞外小泡调节冠状动脉疾病中巨噬细胞的免疫表型

冠状动脉疾病（CAD）是一个重大的健康问题。这项研究的重点是冠状动脉粥样硬化症患者的心包巨噬细胞和细胞外小泡（sEVs）。在 CAD 患者的巨噬细胞中，保护性标志物的表达减少，促炎受体的水平不变。当使用源自 CAD 心包液的 sEVs 进行刺激时，在源自缓冲液的巨噬细胞中也观察到了类似的变化。sEV 含有 miRNA-6516-5p，可抑制 CD36 并影响巨噬细胞的脂质吸收。这些研究结果表明，sEV 介导的 miRNA 作用导致了 CAD 中保护性心包巨噬细胞的减少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.